Ever wonder what billionaires are worried about?
See ‘pic of the day’ below!
Across Markets…
The Australian sharemarket climbed for a third consecutive session on Wednesday led by a rally in financials after National Australia Bank hit a record high on stronger-than-expected first-quarter results.
The S&P/ASX 200 rose 0.5 per cent, or 48.10 points, to 9007, with materials the only sector of the 11 industry group to not finish higher amid a flurry of earnings reports.
Financial stocks have continued to underpin the bourse this reporting season, with the big four banks adding $72 billion in market capitalisation since the start of results.
NAB rose 4 per cent to $47.14 – the biggest gain since April, after briefly touching a record high of $47.96. The bank reported a 16 per cent increase in
cash earnings to $2.02 billion driven by growth in home lending and business banking. That was about 5 per cent ahead of expectations.
Trading was more mixed for the rest of the big four lenders, with Commonwealth Bank down 1 per cent to $176.25, ANZ 0.3 per cent to $39.23. Westpac added 0.2 per cent to $40.80.
UBS Global Markets executive director Owen Johnston said banks expectations were too low going into the reporting season.
“Investors were a little bit cautious, but what we’ve seen is particularly in lending activity, the outlook has been strong and some of the banks have been holding margins so that speaks to operating leverage,” he said.
Source: AFR
Cyclopharm Secures NIH Approval for Technegas, Boosting US Expansion
Cyclopharm (ASX: CYC) has secured a significant milestone in its US expansion, receiving approval for Technegas at the National Institutes of Health (NIH) and an accompanying purchase order, with installation imminent.
This development comes alongside a recent capital raise to fuel the company’s growth strategy.
Technegas has been approved for clinical use at the NIH in Bethesda, Maryland.
A purchase order has been received, with installation expected in the coming weeks, an important step in the company’s federal market penetration.
This utilisation of the five-year Federal Supply Schedule (FSS) agreement streamlines federal procurement processes for Technegas.
Broader Clinical Applications
The NIH approval opens significant opportunities for Technegas beyond its primary use in diagnosing Pulmonary Embolism (PE).
It allows for expansion into critical areas such as COPD, asthma, ILD, and oncology-related pulmonary care.
The product can also support important longitudinal lung studies.
This broadens Technegas’s clinical utility and presents potential for increased system utilisation and recurring consumables revenue per site.
US Expansion Under Federal Supply Schedule
The NIH installation directly utilises the five-year Federal Supply Schedule (FSS) framework, which Cyclopharm announced on 14 March 2025.
This agreement is crucial for validating Technegas procurement across federal healthcare institutions.
It provides a structured pathway, supporting broader US expansion efforts into federal facilities.
Capital Raise Fuels Growth
Cyclopharm recently completed an A$14 million placement and launched an accompanying A$2 million Share Purchase Plan.
The proceeds from this capital raise are designated for accelerating the US Technegas rollout, advancing next-generation development, and bolstering working capital.
The company has reaffirmed its guidance for 250-300 US installations by H2 2026, underscoring its commitment to aggressive US market penetration.
The NIH approval represents a strong validation for Technegas and a key step in Cyclopharm’s US federal market strategy.
Combined with recent capital raising efforts, the company is well-positioned to accelerate its US expansion, though execution remains a key focus.
Source: SmallCaps
Company: Fin Resources Ltd (ASX:FIN)
Sector: Gold/Mining
Deal Type: Placement
Latest Entry Price: $0.0065
Performance Since Entry: +69%
Company: Eden Innovations (ASX:EDE)
Sector: Construction/Clean Energy
Deal Type: Shortfall
Latest Entry Price: $0.035 with 1:2 option, strike $0.07
Price Performance Since Entry: +529%
Company: Tasman Resources Ltd (ASX:TAS)
Sector: Gold/Silver/Mining
Deal Type: Placement
Latest Entry Price: $0.0125 with 1:2 option, strike $0.02
Price Performance Since Entry: +452%
Company: Locksley Resources Ltd (ASX:LKY)
Sector: REE & Antimony/Mining
Deal Type: Placement
Latest Entry Price: $0.04
Price Performance Since Entry: +338%
Company: CuFe Ltd (ASX:CUF)
Sector: Copper/Mining
Deal Type: Placement
Latest Entry Price: $0.016 with 1:2 option, strike $0.025
Price Performance Since Entry: +225%
Company: Tambourah Metals Ltd (ASX:TMB)
Sector: Gold/Mining
Deal Type: Placement
Latest Entry Price: $0.04
Price Performance Since Entry: +45%
Company: Biotron Ltd (ASX:BIT)
Sector: Biotech
Deal Type: Placement
Latest Entry Price: $0.003 with 1:2 option, strike $0.02
Price Performance Since Entry: 0%
Company: Eclipse Metals Ltd (ASX:EPM)
Sector: REE
Deal Type: Placement
Latest Entry Price: $0.015
Price Performance Since Entry: +53%
Company: Neuren Pharmaceuticals Ltd (ASX:NEU)
Sector: Biotech
Deal Type: On-market purchase
Latest Entry Price: $1.20 – $1.50
Price Performance Since Entry: +1,181%
Company: Dimerix Ltd (ASX:DXB)
Sector: Biotech
Deal Type: Rights Issue
Raise Amount: $800,000
Latest Entry Price: $0.08 with 1:1 option, strike $0.126
Price Performance Since Entry: $0.505 +494%
Sector: Blockchain
Deal Type: Placement
Raise Amount: $1M
Latest Entry Price: $0.02 with 1:1 option $0.08 strike
Price Performance Since Entry: +45%
Company: Critica Limited (ASX:CRI)
Sector: REE
Deal Type: Placement
Raise Amount: $1M
Latest Entry Price: $0.0075 with a 1:1 CRIO
Price Performance Since Entry: +260%
Sector: Lithium
Deal Type: IPO
Raise Amount: $8.6M
Latest Entry Price: $0.09 with 1:2 PL3O
Price Performance Since Entry: +61%
Sector: Gold/Mining
Deal Type: Placement
Raise Amount: $2.3M
Latest Entry Price: $0.026 with 1:2 option $0.032 strike
Price Performance Since Entry: +85%
If you would like more information on future Peak deals, please don’t hesitate to get in touch.
Peak accepts no responsibility for any views expressed and marketing material contained in this email except where the message specifically states otherwise and the sender is authorised to state them to be the views of Peak. Information provided in this email is general advise only and does take account your objectives, financial situation or needs. Before acting on any advice in this email, Peak recommends that you consider whether it is appropriate for your circumstances. If this email contains reference to any financial products, you should obtain the current Product Disclosure Statement (PDS) or other disclosure documents for the particular products and consider this information before making any decisions regarding the products. The Financial Services Guide (FSG) can be found at www.peakassetmanagement.com.au or by telephoning Peak on 1300 304 460
Comments are closed